Hexima Limited

ASX:HXL Stock Report

Market Cap: AU$2.2m

Hexima Valuation

Is HXL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HXL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HXL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HXL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HXL?

Key metric: As HXL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HXL. This is calculated by dividing HXL's market cap by their current revenue.
What is HXL's PS Ratio?
PS Ratio35.2x
SalesAU$61.67k
Market CapAU$2.17m

Price to Sales Ratio vs Peers

How does HXL's PS Ratio compare to its peers?

The above table shows the PS ratio for HXL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.9x
RGS Regeneus
4xn/aAU$1.5m
NC6 Nanollose
9.6xn/aAU$2.9m
BP8 BPH Global
14.4xn/aAU$1.6m
VBS Vectus Biosystems
3.6xn/aAU$4.2m
HXL Hexima
35.2xn/aAU$2.2m

Price-To-Sales vs Peers: HXL is expensive based on its Price-To-Sales Ratio (35.2x) compared to the peer average (7.9x).

Price to Sales Ratio vs Industry

How does HXL's PS Ratio compare vs other companies in the AU Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARX Aroa Biosurgery
3.5x22.8%US$154.64m
IMC Immuron
3.6x59.7%US$11.47m
BNO Bionomics
2.4x-5.3%US$9.52m
CHM Chimeric Therapeutics
1.1xn/aUS$5.29m
HXL 35.2xIndustry Avg. 10.6xNo. of Companies8PS01632486480+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HXL is expensive based on its Price-To-Sales Ratio (35.2x) compared to the Australian Biotechs industry average (10.6x).

Price to Sales Ratio vs Fair Ratio

What is HXL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HXL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HXL's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$37.9m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

7D

0%

1Y

6.1%

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.37

7D

-9.6%

1Y

-17.8%

Medical Developments International

AU$46.8m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.41

7D

-2.4%

1Y

-45.0%